drugset
drugset / Trial / NCT03624010

Open-Label Rollover Study of Levosimendan in PH-HFpEF Patients

NCT03624010 ↗

Phase 2 Completed 35 enrolled Tenax Therapeutics, Inc. Medpace, Inc. · collab
NaSingle-groupOpen-labelTreatment

Summary

PH-HFpEF patients will receive open-label doses of levosimendan and be periodically evaluated for safety in extended use.

Timeline

Start
2019-04-09
Primary completion
2023-04-25
Completion
2023-04-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Levosimendan Other / unclassified 1 mg Intravenous

Indications

diastolic heart failure pulmonary hypertension symptomatic heart failure